Rauwolfia Serpentina

Summary

Rauwolfia Serpentina (CHEMBL3559672) is an approved unknown (ATC C02AA53); indicated across 3 conditions including hypertensive disorder and heart disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: C02AA53 (+2 more)
• Indications: 3 conditions
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3559672
Name	Rauwolfia Serpentina
Type	Unknown
Max phase	4
ATC	C02AA53, C02AA03, C02AA04

Also known as: Hiwolfia, Hyserpin, Koglucoid, Raudixin, Rauserpin, Rauval, Rauvolfia serpentina root, Rauwolfia alkaloids, whole root, Rauwolfia serpentina, Rauwolfia serpentina alseroxylon, Rauwolfia serpentina root

Targets

Targets

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: Lysine-specific demethylase 4E, Fructose-bisphosphate aldolase, Prelamin-A/C, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Menin/Histone-lysine N-methyltransferase MLL, Cytochrome P450 2D6, Cytochrome P450 1A2, Cytochrome P450 2C9.

Bioactivity

ChEMBL activities: 30 potent at pChembl ≥ 5 of 35 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2D6	8.7	Potency	2	nM	CHEMBL_ACT_4998227
CYP2D6	8.7	AC50	2	nM	CHEMBL_ACT_5988312
CYP2D6	8.48	Ki	3.3	nM	CHEMBL_ACT_423082
CYP2D6	8.46	Ki	3.5	nM	CHEMBL_ACT_423086
CYP2D6	8.34	Ki	4.6	nM	CHEMBL_ACT_423083
CYP2D6	8.34	Ki	4.6	nM	CHEMBL_ACT_423088
ADRA2C	8.3	Ki	5	nM	CHEMBL_ACT_478953
CYP2D6	8.24	Ki	5.7	nM	CHEMBL_ACT_423085
LMNA	8.15	Potency	7.1	nM	CHEMBL_ACT_3643853
CYP2D6	8.1	Potency	7.9	nM	CHEMBL_ACT_4961584
CYP2D6	8.1	AC50	7.94	nM	CHEMBL_ACT_6058546
ADRA2A	8.09	Ki	8.2	nM	CHEMBL_ACT_478951
CYP2D6	7.89	Ki	13	nM	CHEMBL_ACT_423087
CYP2D6	7.85	Ki	14	nM	CHEMBL_ACT_423084
ADRA2B	7.84	Ki	14.5	nM	CHEMBL_ACT_478952
LMNA	7.15	Potency	70.8	nM	CHEMBL_ACT_3634520
P22002	6.54	Ki	289	nM	CHEMBL_ACT_478954
CYP1A2	5.4	AC50	3981	nM	CHEMBL_ACT_6046785
HIF1A	5.3	Potency	5012	nM	CHEMBL_ACT_4125854
HIF1A	5.3	Potency	5012	nM	CHEMBL_ACT_4520063
A8B2U2	5.25	Potency	5610	nM	CHEMBL_ACT_4587532
CYP1A2	5.1	AC50	7943	nM	CHEMBL_ACT_6051477
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_4973451
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_4981736
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_5042441
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_5046986
CYP2C9	5	Potency	10000	nM	CHEMBL_ACT_5053580
CYP2C9	5	AC50	10000	nM	CHEMBL_ACT_5999191
CYP3A4	5	AC50	10000	nM	CHEMBL_ACT_6036372
CYP3A4	5	AC50	10000	nM	CHEMBL_ACT_6044796

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertensive disorder	4	MONDO:0005044	EFO:0000537
heart disorder	3	MONDO:0005267	EFO:0003777
cardiovascular disorder	3	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000484	PHASE3	COMPLETED	Treatment of Hypertension

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).